AMCP supports efforts to reduce fraud, waste, and abuse in prescription drug benefit plans
From the AMCP Policy Digest, AMCP's policies regarding drug pricing.
Today, the Administration released a final rule, Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals, along with an interim final rule, Most Favored Nations (MFN) Model. In response, AMCP CEO Susan A. Cantrell, RPh, CAE, released the following statement.
This afternoon, the Trump administration released Executive Orders focused on pharmaceutical pricing. Solving this crisis and delivering real change will require elected officials and health care stakeholders to develop practical, informed, and market-based solutions that make health care and prescription drugs more affordable and accessible to all Americans.
On January 25, 2019, AMCP provided comments to CMS in response to its proposed rule on lowering drug prices and reducing out-of-pocket expenses in the Medicare program. The letter outlines the proposal’s impact on providing plan flexibility to manage protected classes, prohibition against gag clauses in pharmacy contracts, E-Prescribing and the Part D Prescription Drug Program, Part D explanation of benefits, and Medicare Advantage and step therapy in Part B.
The Academy of Managed Care Pharmacy (AMCP) is pleased provide comments to the Centers for Medicare & Medicaid Services (CMS) in response to the proposed rule “Medicare and Medicaid Programs; Regulation to Require Drug Pricing Transparency [CMS-4187-P]” published in the Federal Register on October 18, 2018.
AMCP webinar that reviewed the major provisions contained in a recently released advanced notice of proposed rulemaking from CMS on the International Drug Pricing Index for Part B drugs and a recently proposed rule on the Medicare Advantage and Part D Program.
AMCP webinar that reviewed the major provisions contained in a recently released advanced notice of proposed rulemaking from CMS on the International Drug Pricing Index for Part B drugs and a recently proposed rule on the Medicare Advantage and Part D Program.
AMCP webinar that reviewed the major provisions contained in a recently released advanced notice of proposed rulemaking from CMS on the International Drug Pricing Index for Part B drugs and a recently proposed rule on the Medicare Advantage and Part D Program.
On October 18, 2018, the Centers for Medicare & Medicaid Services (CMS) issued a new proposed rule entitled Medicare and Medicaid Programs; Regulation to Require Drug Pricing Transparency.
AMCP letter to Congressional Leadership asking for the inclusion of 42 CFR Part 2 provisions and Medicare fraud, waste and abuse protections in a final opioid conference report
